

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listing of claims in the application.

Listing of Claims

1. **(Currently Amended)** A composition comprising an antibody, or fragment thereof, formulated with DTPA and ~~an agent selected from the group consisting of DEF, mannitol, methionine, and histidine, in an amount effective to protect the antibody, or fragment thereof, against oxidation.~~
2. **(Canceled)**
3. **(Original)** The composition of claim 1, further comprising EGTA.
4. **(Original)** The composition of claim 1, wherein the concentration of DTPA is from about 1 μ M to about 10 mM.
5. **(Withdrawn- Currently Amended)** The composition of claim 1 ~~2~~, wherein the concentration of DEF is from about 1 μ M to about 5 mM.
- 6-8. **(Canceled)**
9. **(Original)** The composition of claim 1, further comprising an agent that inhibits protein aggregation.
10. **(Original)** The composition of claim 9, wherein the agent that inhibits protein aggregation is selected from the group consisting of polysorbate 80, polysorbate 20, glycerol, and a poloxamer polymer.
11. **(Original)** The composition of claim 10, wherein the agent that inhibits protein aggregation is polysorbate 80 or polysorbate 20 at a concentration of from about 0.001% to about 0.1%.

12. **(Original)** The composition of claim 1, further comprising a buffer that maintains the pH of the composition from about 5.0 to about 8.0.
13. **(Original)** The composition of claim 12, wherein the buffer is selected from the group consisting of phosphate, citrate, Tris, acetate, MES, succinic acid, PIPES, Bis-Tris, MOPS, ACES, BES, TES, HEPES, EPPS, ethylenediamine, phosphoric acid, and maleic acid.
14. **(Canceled)**
15. **(Previously Presented)** The composition of claim 1, wherein the concentration of the antibody is from about 1 µg/mL to about 500 mg/mL.
16. **(Canceled)**
17. **(Previously Presented)** The composition of claim 1, wherein the antibody is a monoclonal antibody, or a fragment thereof.
18. **(Previously Presented)** The composition of claim 1, wherein the antibody is a human antibody, or a fragment thereof.
19. **(Previously Presented)** The composition of claim 1, wherein the antibody or fragment thereof is conjugated to an agent, selected from the group consisting of a toxin, a polymer, an imaging agent and a drug.
20. **(Previously Presented)** The composition of claim 1, wherein the antibody or fragment thereof is microencapsulated.
21. **(Original)** The composition of claim 1, wherein the composition is a pharmaceutical composition.
22. **(Canceled)**
23. **(Currently Amended)** A method for preparing a stabilized protein composition,

comprising formulating an antibody, or fragment thereof, together with DTPA and ~~an agent selected from the group consisting of DEF, mannitol, methionine, and histidine,~~ in an amount effective to protect the antibody, or fragment thereof, against oxidation.

24. **(Canceled)**
25. **(Original)** The method of claim 23, wherein the composition further comprises EGTA.
26. **(Currently Amended)** The method of claim ~~25~~ 23, wherein the concentration of DTPA or EGTA is from about 1 μ M to about 10 mM.
27. **(Withdrawn-Currently Amended)** The method of claim ~~23~~ 24, wherein the concentration of DEF is from about 1 μ M to about 5 mM DEF.
28. **(Canceled)**
29. **(Original)** The method of claim 23, further comprising adding an agent that inhibits protein aggregation to the composition.
30. **(Original)** The method of claim 23, further comprising adding a buffer that maintains the pH from about 5.0 to about 8.0 to the composition.
31. **(Original)** The method of claim 30, wherein the buffer is selected from the group consisting of about 5 mM to about 100 mM phosphate, citrate, Tris, acetate, MES, succinic acid, PIPES, Bis-Tris, MOPS, ACES, BES, TES, HEPES, EPPS, ethylenediamine, phosphoric acid, and maleic acid.
32. **(Canceled)**
33. **(Previously Presented)** The method of claim 23, wherein the concentration of the antibody or fragment thereof is from about 1 μ g/mL to about 500 mg/mL.
34. **(Canceled)**

35. **(Previously Presented)** The method of claim 23, wherein the antibody is a human antibody, or a fragment thereof.
36. **(Previously Presented)** The method of claim 23, wherein the antibody is a monoclonal antibody, or a fragment thereof.
37. **(Previously Presented)** The method of claim 23, wherein the antibody or fragment thereof is conjugated to an agent selected from a toxin, a polymer, an imaging agent or a drug.
38. **(Previously Presented)** The method of claim 23, wherein the antibody or fragment thereof is microencapsulated.
39. **(Original)** The method of claim 23, wherein the composition is a pharmaceutical composition.
40. **(Canceled)**